AR102924A1 - Composiciones anticancerosas - Google Patents
Composiciones anticancerosasInfo
- Publication number
- AR102924A1 AR102924A1 ARP150103980A ARP150103980A AR102924A1 AR 102924 A1 AR102924 A1 AR 102924A1 AR P150103980 A ARP150103980 A AR P150103980A AR P150103980 A ARP150103980 A AR P150103980A AR 102924 A1 AR102924 A1 AR 102924A1
- Authority
- AR
- Argentina
- Prior art keywords
- rna
- prostate cancer
- meth
- poly
- castration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 206010060862 Prostate cancer Diseases 0.000 abstract 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 6
- 229920000193 polymethacrylate Polymers 0.000 abstract 5
- 239000007962 solid dispersion Substances 0.000 abstract 4
- 206010027476 Metastases Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001125 extrusion Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102924A1 true AR102924A1 (es) | 2017-04-05 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103980A AR102924A1 (es) | 2014-12-05 | 2015-12-04 | Composiciones anticancerosas |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20170360707A1 (enExample) |
| EP (2) | EP3842034B1 (enExample) |
| JP (1) | JP6767368B2 (enExample) |
| KR (1) | KR102348325B1 (enExample) |
| CN (2) | CN115837010B (enExample) |
| AR (1) | AR102924A1 (enExample) |
| AU (1) | AU2015358493B2 (enExample) |
| CA (1) | CA2969661C (enExample) |
| CL (1) | CL2017001372A1 (enExample) |
| CO (1) | CO2017005573A2 (enExample) |
| CR (1) | CR20170217A (enExample) |
| CY (1) | CY1123856T1 (enExample) |
| DK (1) | DK3226842T3 (enExample) |
| EA (1) | EA035988B1 (enExample) |
| ES (2) | ES2839128T3 (enExample) |
| HR (1) | HRP20201902T1 (enExample) |
| HU (1) | HUE051888T2 (enExample) |
| IL (1) | IL252324B (enExample) |
| LT (1) | LT3226842T (enExample) |
| MA (2) | MA55404A (enExample) |
| MD (1) | MD3226842T2 (enExample) |
| MX (1) | MX384382B (enExample) |
| NI (1) | NI201700069A (enExample) |
| PL (1) | PL3226842T3 (enExample) |
| PT (1) | PT3226842T (enExample) |
| RS (1) | RS61466B1 (enExample) |
| SG (1) | SG11201704264UA (enExample) |
| SI (1) | SI3226842T1 (enExample) |
| TW (1) | TWI683662B (enExample) |
| UA (1) | UA121123C2 (enExample) |
| WO (1) | WO2016090101A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3305285T (pt) | 2012-09-26 | 2020-11-24 | Aragon Pharmaceuticals Inc | Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático |
| CA2969675C (en) | 2014-12-05 | 2023-06-06 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| BR112017011788A2 (pt) | 2014-12-05 | 2017-12-26 | Aragon Pharmaceuticals Inc | composições anticâncer |
| EP4438126A3 (en) | 2017-10-16 | 2025-01-01 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| JP7244536B2 (ja) * | 2018-04-06 | 2023-03-22 | キャプシュゲル・ベルジウム・エヌ・ヴィ | メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法 |
| WO2020144646A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Apalutamide dispersed in applesauce for treating prostate cancer |
| WO2020157699A1 (en) | 2019-01-30 | 2020-08-06 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| BR112021014657A2 (pt) | 2019-01-30 | 2021-09-21 | Janssen Pharmaceutica N.V. | Métodos para tratar câncer de próstata com base em subtipos moleculares |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP4054572A1 (en) | 2019-11-04 | 2022-09-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2024189186A1 (en) | 2023-03-16 | 2024-09-19 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030087048A (ko) | 2001-04-02 | 2003-11-12 | 아스트라제네카 아베 | 4-시아노-트리플루오로-3-(4-플루오로페닐설포닐)-2-히드록시-2-메틸프로피오노-ｍ 톨루이다이드 및 ｐｖｐ를포함하는 고체 약학 조성물 |
| JPWO2003077827A1 (ja) * | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | 医薬固体分散体の製造方法 |
| WO2005055987A1 (en) * | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER |
| PL3412290T3 (pl) * | 2006-03-27 | 2021-09-06 | The Regents Of The University Of California | Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym |
| EA028869B1 (ru) * | 2010-02-16 | 2018-01-31 | Арагон Фармасьютикалс, Инк. | Модуляторы рецептора андрогенов и их применение |
| WO2012174436A1 (en) * | 2011-06-15 | 2012-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| ES2809738T3 (es) | 2012-06-07 | 2021-03-05 | Aragon Pharmaceuticals Inc | Formas cristalinas de un modulador de receptor de andrógenos |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| WO2014043208A1 (en) * | 2012-09-11 | 2014-03-20 | Medivation Prostate Therapeutics, Inc. | Formulations of enzalutamide |
| PT3305285T (pt) * | 2012-09-26 | 2020-11-24 | Aragon Pharmaceuticals Inc | Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| EA028009B1 (ru) * | 2013-01-22 | 2017-09-29 | Ф.Хоффманн-Ля Рош Аг | Фармацевтическая композиция с улучшенной биодоступностью |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| WO2015023710A1 (en) * | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| MX386859B (es) * | 2014-02-05 | 2025-03-19 | Lek Pharmaceuticals | Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos. |
-
2015
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 MX MX2017007201A patent/MX384382B/es unknown
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 ES ES20209559T patent/ES3021508T3/es active Active
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 HR HRP20201902TT patent/HRP20201902T1/hr unknown
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 CN CN202211487545.0A patent/CN115837010B/zh active Active
- 2015-12-03 EP EP20209559.2A patent/EP3842034B1/en active Active
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro not_active IP Right Cessation
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh not_active IP Right Cessation
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en not_active Ceased
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active Active
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102924A1 (es) | Composiciones anticancerosas | |
| NI201700068A (es) | Composiciones anticancerosas | |
| CO2017005572A2 (es) | Composiciones anticancerígenas | |
| CL2016000783A1 (es) | “compuestos derivados de isoquinolinona y quinazolinona, inhibidores pi3k; composición farmacéutica que los comprende; útiles en el tratamiento del cáncer, enfermedades inflamatorias y autoinmune”. pct | |
| MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
| MX2019009848A (es) | Proteínas que se unen a her2, nkg2d y cd16. | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| NI201800127A (es) | Composiciones antineoplásicas | |
| DOP2015000108A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
| MX2020005344A (es) | Compuestos de pirazolopiridinona. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |